Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States
The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.
Indinavir (Crixivan, IDV)
Last Updated: December 7, 2018; Last Reviewed: December 7, 2018
|Formulation||Dosing Recommendations||Use in Pregnancy|
Note: Must be combined with low-dose RTV boosting in pregnancy.
|Standard Adult Dose
Without RTV Boosting:
PK in Pregnancy:
Dosing in Pregnancy:
|Minimal placental transfer to fetus.b
No evidence of human teratogenicity in cases reported to the Antiretroviral Pregnancy Registry (can rule out 2-fold increase in overall birth defects).
Must be given as low-dose, RTV-boosted regimen in pregnancy.
Theoretical concern regarding increased indirect bilirubin levels, which may exacerbate physiologic hyperbilirubinemia in neonates. Minimal placental passage mitigates this concern.
Given the available alternative ARVs, IDV is not recommended for treatment of pregnant women in the United States.
a Individual ARV drug dosages may need to be adjusted in patients with renal or hepatic insufficiency (for details, see the Adult and Adolescent Guidelines Appendix B, Table 8).
Key to Acronyms: ARV = antiretroviral; IDV = indinavir; PK = pharmacokinetic; RTV = ritonavir
- AIDSinfo Drug Database
- AIDSinfo Patient Materials: Preventing Mother-to-Child Transmission of HIV
- AIDSinfo Patient Materials: HIV Medicines During Pregnancy and Childbirth
- AIDSinfo Patient Materials: Protecting Baby from HIV
- AETC National HIV Curriculum
- How to Cite These Guidelines
- Perinatal Guidelines Archive